Location History:
- Lansdale, PA (US) (1999 - 2000)
- Ambler, PA (US) (2003)
Company Filing History:
Years Active: 1999-2003
Title: The Innovative Contributions of Mandana Asgharnejad
Introduction
Mandana Asgharnejad is a prominent inventor based in Lansdale, PA (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit HMG-CoA reductase and compositions for inhibiting platelet aggregation. With a total of 4 patents to her name, her work has the potential to impact the treatment of various diseases.
Latest Patents
One of her latest patents is focused on "Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors." This invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, which is crucial for treating and reducing the risk of diseases affected by this enzyme. The invention emphasizes the oral administration of a therapeutically effective amount of a compound selected from a dihydroxy open acid statin in a delayed-release pharmaceutical dosage form. This ensures that the substantial release of the compound occurs after the dosage form has passed through the stomach.
Another notable patent is for "Compositions for inhibiting platelet aggregation." This invention includes a pharmaceutical composition for oral administration that comprises a pharmaceutically effective amount of a specific compound, along with polymeric binders and excipients. The process for making this pharmaceutical composition is also detailed in the patent, showcasing her innovative approach to drug formulation.
Career Highlights
Mandana Asgharnejad is currently associated with Merck & Company, Inc., a leading global healthcare company. Her work at Merck has allowed her to focus on developing innovative pharmaceutical solutions that address critical health issues.
Collaborations
Throughout her career, Mandana has collaborated with notable professionals in her field, including Jerome P Draper and David C Dubost. These collaborations have likely contributed to the success and impact of her inventions.
Conclusion
Mandana Asgharnejad's contributions to pharmaceutical innovation are noteworthy, with her patents reflecting a commitment to improving health outcomes. Her work continues to pave the way for advancements in the treatment of diseases related to HMG-CoA reductase and platelet aggregation.